Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Alimta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Alimta was produced by Lilly.

Roche’s Tecentriq misses survival mark in frontline NSCLC

Roche’s Tecentriq misses survival mark in frontline NSCLC

Roche’s PD-L1 inhibitor Tecentriq (pemetrexed) was unable to meet the threshold for a significant improvement in overall survival (OS) when added to Eli Lilly’s Alimta (pemetrexed) and platinum

MSD wins key EU approval for Keytruda, Alimta combo

MSD wins key EU approval for Keytruda, Alimta combo Decision keeps Keytruda well ahead of rival Tecentriq. Immunotherapy blockbuster Keytruda has received another boost with the European approval of its use in combination with Lilly’s Alimta plus chemotherapy in ... Compared to those on Alimta and

Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline

Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline For years, Lilly’s presence in cancer has been led by lung cancer chemotherapy drug Alimta (pemetrexed), which brought in $2bn in sales last year but has been gradually declining from

Roche eyes September FDA verdict for triple NSCLC therapy

Roche eyes September FDA verdict for triple NSCLC therapy of carboplatin and Celgene’s Abraxane (nab-paclitaxel) and Eli Lilly’s Alimta (pemetrexed) in first-line non-squamous NSCLC – IMpower130 and IMpower132 respectively, with results due in the coming months.

Sanofi’s latecomer PD-1 gets date for FDA verdict

Sanofi’s latecomer PD-1 gets date for FDA verdict The agency has granted Keytruda a priority review in combination with Lilly’s Alimta (pemetrexed) and platinum-chemotherapy as a first-line treatment for patients with metastatic non-squamous NSCLC.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics